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I)' Renal Transplantation in Children Managed With 
Lymphocyte Depleting Agents and Low-Dose 
Maintenance Tacrolimus Monotherapy 
Demetrius Ellis,1,4 Ron Shapiro,2 Michael Moritz, 1 Abhay Vats/ Amit Basu/ Henkie Tan/ Liise Kayler/ 
Janine Janosky,3 and Thomas E. Starze 
Objective. Describe the safety and efficacy of antithymocyte globulin or alemtuzumab preconditioning, ste-
roid avoidance and reduced calcineurin inhibitor (CN!) immunosuppression in 34 children undergoing renal 
transplantation. 
Methods. ATG (n=8) or alemtuzumab (n=26) were infused at the time of transplantation. This was followed by 
low-dose twice a day tacrolimus monotherapy with consolidation to once daily dosing by 6 months and once every 
other day dosing by 12 months. Follow-up ranged from 0.5-2.9 years (mean 1.33 years), with a minimum of6 months. 
Results. Both ATG and alemtuzumab were well tolerated. Lymphopenia occurred routinely and resolved after 3-6 
months. Acute cellular rejection occurred in 9%; it was related to medical nonadherence in two patients and resulted in 
one graft loss at 1.5 years. Important adverse events included transient neutropenia in 10 children (none with serious 
infection), and autoimmune hemolytic anemia in two (resolved with a steroid course in both and conversion to 
sirolimus in one). Estimated glomerular filtration rate (e-GFR) was stable and averaged 88 mLimin/I.73 m2 at latest 
follow-up. Fifteen preadolescents had a greater increase in height Z-score at 1 year (1.3 vs. 0.5, P=O.OOI), and a higher 
e-GFR (94.8:!:21 vs. 76.6:!:20 mllmin/1.73 m2 , P<0.05), when compared to case-matched historical controls who were 
weaned off steroids by 6 months after transplantation and received twice daily tacrolimus mono therapy. 
Conclusion. This simple regimen appears safe, has a low risk for acute cellular rejection or other adverse effects, and is 
associated with excellent growth and renal function. Such a regimen may also improve compliance and limit CNI 
nephrotoxicity. 
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(Transplantation 2007;83: 1563-1570) 
There has been little improvement in renal allograft sur-
vival during the years between 1995 and 2000, mainly 
because of an inability to prevent chronic allograft nephrop-
athy (CAN) (1-4). Major contributors to CAN are acute and 
chronic rejection, and nephrotoxicity associated with the 
long-term use of calcineurin inhibitors (CNI) (5). Recent 
studies have demonstrated that preconditioning with anti-
thymocyte globulin (ATG) or alemtuzumab (Campath-lH, 
an anti-CD52 antibody), to aggressively deplete T-cell clones 
prior to transplantation, together with maintenance CNI, ef-
fectively suppresses acute cellular rejection (ACR) without 
the need of corticosteroids (6-12). This nonmyeloablative 
regimen, which does not destroy bone marrow stem cells 
(13), may facilitate immunologic engagement between the 
recipient and donor leukocyte subpopulations, possibly by 
modifying the function of dendritic cells, thereby enhancing 
long-term engraftment or "tolerance" (14, 15). It has also 
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been further theorized that minimizing maintenance tacroli-
mus immunosuppression may enable more controlled 
immunologic interactions between donor and recipient im-
mune systems, and may be more "tolerogenic" while limiting 
chronic CNI nephrotoxicity (16,17). Such simple tacrolimus 
monotherapy regimen may be especially advantageous to the 
pediatric renal transplant population as it may obviate the 
stunted growth, obesity, hypertension, and body disfigure-
ment and associated drug noncompliance which continues to 
plague current multidrug immunosuppressive regimens that 
include steroids. Also, a low rate of ACR together with lower 
chronic tacrolimus exposure may limit CNI nephrotoxicity 
and may potentially permit longer allograft survival. 
Experience with preconditioning agents in pediatric re-
nal recipients is limited. In one study, good allograft survival 
was obtained in 17 children managed with short-term Thy-
moglobulin induction followed by a multidrug maintenance 
immunosuppression regimen (18). In another report, Cam-
path induction followed by variable maintenance immuno-
suppressive regimens was associated with ACR in three of 
four children (19). A protocol was recently developed at our 
center utilizing a preconditioning agent at transplantation, 
followed by steroid avoidance and weaning of tacrolimus, 
and was very effective in adults undergoing renal transplan-
tation (10, 16). This paradigm was then adopted in children 
and resulted in very encouraging preliminary results (20). 
The current report extends our experience to 34 pediatric 
renal transplant recipients and provides a comprehensive 
evaluation of the benefits and risks of the current protocol 
over a longer follow-up time. 
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PATIENTS AND METHODS 
Lymphocyte depletion, with either rabbit antithymo-
cyte globulin (ATG, Thymoglobulin; Sangstat Medical Corp., 
Fremont, CAl or with alemtuzumab (Campath-lH; Millen-
nium Pharmaceuticals, Cambridge, MA), followed by tacroli-
mus (Prograf; Fujisawa, Deerfield, IL) monotherapy, has 
been the standard of care in renal transplant recipients at 
Children's Hospital of Pittsburgh from May 2003 to the 
present. Consent and assent forms were obtained after ap-
proval by the Innovative Practices and Pharmacy and Thera-
peutic Committees for off-label use of Campath. The current 
study had no funding source except for the current retrospec-
tive data analysis (Astellas Pharmaceutical Grant). 
Thirty four consecutive children ranging in age from 
1-18 years who met the minimum criterion of 6 months of 
follow-up by December 2005 were included in the current 
analysis. The diagnosis and other pertinent clinical data of the 
recipients are shown in Table 1. The surgical procedure and 
fluid management were standard (21) except for the place-
ment of double-J ureteral stents for 3-4 weeks in the majority 
of the children. ATG was utilized in the initial eight children. 
Because Campath has relatively fewer infusion reactions, 
greater potency (6, 7), and longer effect, possibly due to its 
half-life of2-3 weeks (22), it was utilized in the subsequent 26 
recipients. 
ATG (5 mg/kg body weight) or Campath (0.4-0.5 
mg/kg body weight) were given intravenously over a period of 
3-6 hr starting at transplantation with completion before the 
cross clamp release. Intravenous methylprednisolone (10-15 
mg/kg body weight) was given just prior to the antibody in-
fusion for prevention of cytokine release syndrome, and this 
dosage was repeated during the arterial anastomosis. Tacroli-
mus was begun on the day after transplantation either orally 
(0.2 mg/kg body weight divided in two dosages per day) or 
intravenously (0.1 mg/kg body weight over 24-hours), and 
the dosage was adjusted to attain blood levels of lO::t 2 ng/mL 
measured by immunoassay (Abbott Diagnostics). After about 
1 month, a level of 6-10 ng/mL was acceptable in most recip-
ients without ACR and absence of panel reactive antibodies. 
After 4-6 months, recipients who had not experienced acute 
rejection received the total daily tacrolimus dose as a single 
dose (consolidation), and after 10-12 months this same dos-
age was given on alternate days (spaced weaning) without 
regard to target blood levels. 
All children received valganciclovir (Vaicyte, Roche, 
Nutley, NT) at an oral dosage of 450 mg/I.73 m2 once daily for 
a period of 6 months. Valganciclovir prophylaxis was ex-
tended to I-year in all seronegative recipients of Epstein-Barr 
virus (EBV) and/or cytomegalovirus (CMV) seropositive do-
nor grafts who also received a single prophylactic intravenous 
dose of cytomegalovirus immune globulin (100 mg/kg body 
weight; CytoGam, MedImmune, Gaithersburg, MD) on the 
day after transplantation. Other routine prophylactic medi-
cations included Mycostatin 300,000-500,000 units given by 
the swish and swallow method four times daily for 4 months; 
trimethoprim-sulfamethoxazole (Bactrim, 2 mg/kg/day, or 
maximum of 40 mg/day, based on trimethoprim content), 
daily for 1 month and then three times per week indefinitely; 
and aspirin 81 mg/day for 2-4 weeks. Gastroprotective agents 
were given intraoperatively and for 2-6 weeks subsequently, 
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TABLE 1. Selected clinical data in 34 children 
receiving Thymoglobulin or Campath preconditioning at 
the time of transplantation 
Characteristic 
Age, mean::'::SEM 
Range (years) 
Indications for transplantation 
Congenital uropathy (n= 14) 
Hypodysplasia 
Posterior urethral valves 
Other 
Acquired glomerulopathy (n=9) 
Focal glomerulosclerosis 
Other 
Hereditary/familial (n= 10) 
Nephronophthisis 
Male 
Congenital nephrotic syndrome 
Other 
Preadolescent 
Retransplantation 
Other transplants 
Dialysis/pre-emptive 
Living donor/cadaveric 
Cold ischemia time (mean hours) 
Average length of stay (days) 
One-year allograft survival (%) 
PRA >20% 
ABDR HLA mismatch (mean::'::SD) 
Follow-up 
6-month (n) 
2: I-year (n) 
Mean::'::SEM, years 
Overall years (mean±SD) 
Blood tacrolimus levels (ng/mL, 
mean±SD) 
1 month 
3 months 
6 months 
1 year 
Latest follow-up 
a Both liver, small bowel. 
b Twelve PD, 5 HD, 5 PD and HD. 
C Two unrelated. 
Data 
10.1::':: 1.1 
1-18 
5 
4 
5 
3 
6 
3 
2 
5 
19 
22 
3 
2a 
22112b 
23/W 
24.5 
12.2 
100 
2 
3.3::':: 1.3 
34 
25 
1.84±0.12 
1.33::'::0.75 
9.9::'::2.6 
8.7±2.2 
7.0±2.6 
5.0±1.75 
2.7± 1.75 
as needed. Supplemental magnesium or Bicitra were utilized 
selectively. 
Serial measurements of human leukocyte antigen class 
I and II antibodies were performed by enzyme-linked immu-
nosorbent assay testing. Individuals with antibody titers ex-
ceeding 10% had further testing for donor specific antibodies 
(DSA; Elisa, Lambda Antigen Tray-Mixed, One Lambda) to 
aid in the determination of immunological risk for humoral 
rejection before tacrolimus weaning. 
Patients were evaluated closely for hematologic and in-
fectious complications. Automated and manual blood pres-
uf Hl 
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sures and growth parameters were recorded. Estimated 
glomerular filtration rate (e-GFR) was calculated by Schwartz 
formulas (23). Growth was assessed by multiple parameters 
as previously outlined (24). Because height age lags behind 
the chronological age in children with chronic renal failure 
(23), in the current series we used the height age to assess 
changes in body mass index (BMI) and weight for height 
index (WHI). Growth and GFR could not be assessed in three 
children with severe orthopedic or neurological disorders 
(VATER syndrome, spina bifida). Their latest serum creati-
nine levels were 0.7, l.1 and 0.6 mg/dL, respectively. 
Data were abstracted from the chart utilizing an "hon-
est broker" method and patients were de-identified prior to 
analysis under the University of Pittsburgh institutional re-
view board guidelines. 
Statistical Methods 
The ATG and Campath subgroups were clinically in-
distinguishable permitting analysis of the combined patient 
series. Descriptive data are expressed as means::!:: standard de-
viation. Two independent sample t test analyses were pre-
formed for non-growth data comparisons. We compared 
growth data from each time point to the next, and between 
adolescents and non-adolescents. A non-parametric Mann-
Whitney test was applied to comparisons of GFR and growth 
data. Growth data were also analyzed by the more conserva-
tive Wilcoxon signed rank test which takes into consideration 
that a few children did not have growth data at each time 
point of evaluation. The P values shown below reflect these 
more conservative results. Statistical significance was defined 
by a P value <0.05. 
Growth and GFR in 15 preadolescent children were 
also compared with data of 15 case-matched historical con-
trols managed with our prior protocol of twice daily tacroli-
mus with steroid weaning and withdrawal by 6 months after 
transplantation (24). 
RESULTS 
As shown in Table I, our unselected patients had typical 
pediatric renal disorders leading to renal failure. Eight chil-
dren were black and 26 were white. The majority received 
living donor grafts. The mean follow-up time was 1.33 years. 
Twenty-five children were maintained on the current protocol 
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for a period ranging from 1.0 to 2.9 years. The initial length of 
hospital stay was 12.2::!::6.S days (mean::!::SD). Six infants with 
major preexisting gastrointestinal disorders (gastrostomy 
tubes and/or colostomies) had longer hospital stays; exclud-
ing such infants, the average length of hospital stay was 10 
days. 
As noted in Table 1, tacrolimus blood levels diminished 
during the first 6 months after transplantation, and fell fur-
ther after 6 months with decreasing dosing frequency and 
longer trough time. Among the 34 children maintained on 
this protocol for ~S months, 6 were not considered eligible 
for once daily tacrolimus dosing consolidation because of 
early or late ACR, or because of fluctuating serum creatinine 
concentrations related to bladder dysfunction. A total of27 of 
the remaining 28 children, or 96%, were successfully switched 
to once daily tacrolimus dosing at SA::!:: 1.9 months 
(mean::!::SD; range 3-10.5 months) after transplantation. 
Also, after excluding one child who experienced late ACR, 17 
of 18 children, or 94%, with long enough follow-up to permit 
spaced tacrolimus monotherapy were successfully switched 
to every other day dosing at ILl ::!::2.7 months (mean::!::SD, 
range 7 -IS months) and at latest follow-up their mean trough 
tacrolimus level is 2.7 ng/mL. However, 2 of these 17 children 
(12%) returned to once daily dosing at 1.5 and 2.3 years, 
respectively, based on the appearance of DSA. Neither child 
had a change in e-GFR. 
Hematologic data are summarized in Table 2. Com-
pared to pretransplantation, the white blood cell count 
(WBC) decreased gradually and reached a nadir at 3 months 
after transplantation (P<O.OOI), followed by recovery by 1 
year after transplantation. The initial decrease in WBC was 
mainly due to the fall in lymphocytes which occurred within 
one week of preconditioning with ATG or Campath; WBC 
began to recover by 1 month, with a slower recovery subse-
quently, and full recovery by 1 year of transplantation. The 
proportion of neutrophils did not change appreciably compared 
to pretransplant values. However, the absolute neutrophil count 
(ANC) fell significantly during the first 6 months and reached a 
nadir of2, 123::!:: 734/mm3 at 3 months (P<O.OO 1, for all intervals 
between 1 and 6 months compared to baseline ANC). While the 
ANC improved subsequently, it remained below baseline values 
at both 1 year and at latest follow-up but did not differ signifi-
cantly from baseline ANC (P= NS). 
TABLE 2. Hematologic data in 34 children with renal allografts after Thymoglobulin or Campath preconditioning 
WBC Lymphocytes Neutrophils (ANC) Platelets Hemoglobin (gldL) 
Pretransplant 8.33±3.76 36.21 ± 13.22 49.62±13.43 (4.13) 294±120 1O.8± 1.9 
1 week 6.95±3.42 4.69±5.57 79.21±15.87 (5.46) 232±99 10.1 ± 1.5 
2 weeks 5.99±3.28 6.73±6.07 76.71±17.32 (4.57) 378±133 9.8±1.8 
1 month 4.93±2.56 18.34± 18.68 68.25± 19.26 (3.22t 329±112 1O.6±2.4 
6 weeks 4.19±2.19 19.60± 16.35 66.36± 17.13 (2.80)" 323±1l7 9.9±1.3 
3 months 3.51±1.15 24.00± 13.36 61.68± 15.44 (2.12)a 269±97 10.8±1.5 
6 months 4.77±1.99 27.82±14.84 58.82± 15.24 (2.76t 301±119 11.6± 1.5 
1 year 6.00±3.54 36.00± 16.15 50.35± 15.42 (3.02) 277±116 11.8±2.8 
Latest follow-up 6.43±2.76 35.85± 12.22 50.30± 14.21 (3.15) 282±71 12.3±1.2 
All WBC and platelet values are in the thousands/mm3 while lymphocytes and neutrophils are expressed as percent of a total WBe. All values are means±SD. 
a P<O,OOI compared to baseline absolute neutrophil count (ANC) in thousands/mm'. 
pnhit, 
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Table 3 lists the complications encountered in our pa-
tients. ACR occurred in three children (9%) with cadaveric allo-
grafts. All three received Campath, and one lost their allograft at 
1.5 years. ACR developed in a highly sensitized child during the 
first 2 weeks of transplantation, while biopsy-confirmed rejec-
tion occurred at 1 year and at 1.5 years after transplantation in 
two noncompliant children, including a sensitized teenager with 
previous allograft loss due to noncompliance. 
children were normotensive while several needed fewer antihy-
pertensive medications. Only three children developed new 
onset hypertension, which resolved by 3 months after transplan-
tation. The prevalence of hypertension was 34% at 3 months and 
only 15% at latest follow-up. On latest follow-up, two of five 
(40%) required two or more antihypertensive medications com-
pared to 14 of 19 (74%) prior to transplantation. 
Neutropenia and anemia were the most important 
complications. When neutropenia was defined as an ANC 
<1500/mm3 , it occurred in 10 (29%) children, with onset 
mainly between 3 weeks and 6 months. Antineutrophilic an-
tibodies were absent in several children tested for this disor-
der. One child (3%) had neutropenia prior to transplantation 
compared to 18-20% between 1 and 6 months after trans-
plantation, and 10% subsequently. One asymptomatic child 
had an ANC of 986, which reversed spontaneously after sev-
eral days. Filgrastrim (Neupogen; Amgen, Thousand Oaks, 
CAl was given to four children with an ANC < 1000/mm3• An 
infant with several bouts of otitis media had the longest 
Seven children (21%) developed bacterial infections; 
only one with urosepsis required hospitalization. Although 
16 children were seronegative for EBV and 16 were seroneg-
ative for CMV at the time of transplantation while their do-
nor was seropositive for these viruses, there was no instance of 
EBV or CMV disease, or posttransplant lymphoproliferative 
disease (PTLD). Asymptomatic EBV and CMV seroconver-
sion occurred in five children (four had a rise in EBV poly-
merase chain reaction and one had CMV seroconversion). 
Prior to transplantation, 19 of 34 (56%) children had 
hypertension. At 1 month after transplantation, 4 of these 19 
TABLE 3. Complications and adverse effects linked to Thymoglobulin or Campath preconditioning followed by 
tacrolimus monotherapy in 34 children with renal transplants 
Complication/adverse effect 
General 
Cytokine release syndrome 
Delayed graft function 
Acute cellular rejection (ACR) 
Infection (sepsis, pneumonia, cellulitis, 
wound infection pyelonephritis, otitis 
media) 
Recurrent focal glomerulosclerosis 
Feeding problems or functional bowel 
obstruction 
Hypertension (new onset) 
Microscopic hematuria/sterile pyuria 
Acute pancreatitis 
Unexplained ascites 
Hematologic disorders 
Neutropenia 
Anemia, nonhemolytic 
Anemia, hemolytic 
Metabolic disorders 
Posttransplant diabetes (new onset) 
Hypomagnesemia «1.3 mgldL) 
Metabolic acidosis (tC02 <20 mEq/L) 
Hyperkalemia (>5.5 mEq/L) 
Hyperlipidemia 
Hyperuricemia 
" 
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Number of 
children affected 
None 
5 
3 
7 
4 
3 
8 
10 
4 
2 
2 
12 
11 
6 
2 
2 
Comment 
Prevented with 2 perioperative dosages of steroids 
All had prolonged cold ischemia time; 2 needed dialysis. All recovered 
within 3 weeks 
One was a highly sensitized child whose renal function improved with 
plasmapheresis; in 2 ACR was linked to noncompliance 
No EBV or posttransplant lymphoproliferative disease; no CMV, 
parvovirus, or polyoma virus encountered 
Successfully managed with plasmapheresis 
All were infants with prior feeding problems, colostomies, and 
gastrostomy tubes 
None of these 3 children required antihypertensive agents beyond 3 
months (see text and Table 4) 
Hematuria was not accompanied by bacterial or viral infection, and 
resolved after ureteral stent removal 
Resolved spontaneously 
Transudate and not urinoma; resolved after one paracentesis 
Onset 3 weeks to 6 months; duration 0.5-7 months. Neupogen utilized 
in 4 of5 children with ANC < IOOO/mm3 • Cellulitis occurred in I; no 
serious infection in other 4. 
Responded to erythropoietin in 3 and to iron in 1. Off erythropoietin 
after 2 to 5 months of therapy 
Both autoimmune (see text) 
Developed in one child with rapid obesity, recurred in another with 
prior diabetes 
Medically controlled. Uncommon after 6 months 
Medically controlled. Uncommon after 6 months 
Medically controlled. Uncommon after 6 months 
Transient. Resolved without drug use 
One of2 had mild allograft dysfunction 
V' k: rrclll~l1ori !"mrnCllictIOIIOf 
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course of filgrastim administration comprising 4 months. 
Another infant had a Staphylococcal urinary tract infection in 
the first month of transplantation, while a teenager developed 
foot cellulitis after a track meet at 5 months; both responded 
to a total of two and three dosages of filgrastim each. A fourth 
child developed neutropenia combined with hemolytic 
anemia and received filgrastim for 2 months as well as eryth-
ropoietin for 7 months. In all neutropenic children valganci-
dovir was changed to once every other day dosing. In the 
remaining five children with an ANC > 1000/mm3, infections 
were uncommon and included conjunctivitis, transient 
mouth sores, gastroenteritis, upper respiratory infection, and 
recurrent urinary tract infection in a child with a neurogenic 
bladder. 
Prolonged anemia occurred in a total of four children. 
Coombs-positive hemolytic anemia requiring hospitalization 
developed at 7 months in a child who received Campath, and 
at 12 months in a child who received ATG. In the first child, 
the disorder resolved after a brief course of steroids and 
change in tacrolimus to every other day dosing. In the second 
child, steroids were also given along with a reduction in ta-
crolimus dose followed by conversion to cydosporine; these 
measures were ineffective but hemolysis did resolve after con-
version to sirolimus. Erythropoietin was transiently adminis-
tered to three children. Thrombocytopenia was not observed. 
Among metabolic disorders, new onset diabetes 
occurred in only one child and recurred in another with pre-
viously resolved posttransplant diabetes. Electrolyte distur-
bances were usually encountered during the initial 3 months 
and included hypomagnesemia, metabolic acidosis, and hy-
perkalemia. These disturbances were managed using magne-
sium oxide or magnesium gluconate, bicarbonate or sodium 
citrate/citric acid, and fludrocortisone (Florine£). There were 
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no associated significant muscle cramps or weakness, seizures 
or other symptoms. At latest follow-up, only three children 
required magnesium and/or alkali supplements, and one re-
quired fludrocortisone to control hyperkalemia. 
Growth data are summarized in Table 4. In the group as a 
whole, height Z-score increased significantly at all time points 
compared to the time of transplantation (P:50.00 1). The change 
in height Z-score was also statistically significant between 6 
months and 1 year as well as between 6 months and at latest 
follow-up (both, P=0.005), and also between 1 year and latest 
follow-up (P=0.02). As noted in Table 4, in the preadolescent 
group height Z-score increased by 1.3 and by 1.7 standard devi-
ations at 1 year and at latest follow-up, respectively, compared to 
the time of transplantation (P= 0.00 1). By comparison, in the 15 
case-matched historical controls, the change in height Z-score at 
1 year was 0.5 standard deviations (P=0.02, current versus con-
trol cases). Accelerated or catch-up growth, defined as a change 
in Z-score ;::0.5 SD/year, occurred in 92% and 91 % of preado-
lescents and in 33% of adolescents at 1 year and at latest follow-
up, respectively. In the adolescent subgroup height Z-score also 
improved and catch-up growth occurred in 33% at I-year after 
transplantation but these differences were not statistically signif-
icant. Height velocity was 11.75 em/year in the preadolescent 
subgroup compared to 10 cm/year in the controls (P=NS). 
BMI did not change after transplantation. WHI rose from 
2.8 to 8.9 during the first year of transplantation (P=O.Ol) but 
fell to the 6-month level at latest follow-up. New onset obesity 
did not occur in any of the children, although it persisted in three 
children who were obese prior to transplantation. 
Renal function and selected electrolyte values are de-
picted in Table 5. Transient proteinuria occurred in two of 
the three children managed for ACR and in another child 
with focal glomerulosclerosis. GFR ranged from 82-96 mLl 
TABLE 4. Growth data at different time points after renal transplantation with Thymoglobulin or Campath 
preconditioning 
BMlfor 4BMlfor 
N Age Z-score 4Zscore height age height age WHlindex 4WHlindex 
Combined preadolescent 
and adolescent 
groups 
At transplant 31 1O.2±6.3 -1.B±1.B IB.2±2.B 2.3±20.4 
6 months 26 11.3±6.1 -1.4±0.6" 0.5±0.6 1B.1 ±2.6 -O.2±1.9 B.9±16.1 6.7±12.6 
1 year IB 10.9±6.1 -O.9±O.l7a 0.9±0.7 17.9±2.6 -0.5±2.3 13.7±B.4 7.B± 15.0 
Latest follow-up 17 11.7±6.B -O.4±IS 1.2± 1.1 IB.3±2.7 -O.3±2.6 7.6±20.1 4.5±17.9 
Preadolescent group 
At transplant 19 6.1±4.3 -3.1 ± 1.65 16.7±2.4 2.B± IB.2 
6 months 15 7.0±4.3 -2.4±1.B" 0.6±0.5 16.2±1.l -O.5±2.4 4.0±7.B 3.4± 14.5 
1 year 12 7.5±4.6 -1.4± 1.9" 1.3±0.7" 16.4± 1.3 -O.9±2.7 8.9± 13.0b 4.7± 17.4 
Latest follow-up 11 7.B±5.0 -0.7±1.7a 1.7± LOa 16.6±1.6 -0.8±3.0 4.2±9.8b -1.1 ±18.Bb 
Adolescent group 
At transplant 12 16.B± 1.4 -O.4±O.9 20.4± 1.4 1.5±24.3 
6 months 11 17.2± 1.4 -0.2± 1.0 0.2±0.3 20.7±1.3 O.2±0.6 15.7±21.B 11.2±8.2 
1 year 6 17.5± 1.3 O.O± 1.0 0.3±0.2 20.9± 1.6 0.2± 1.1 23.2±24.9 14.1±5.5 
Latest follow-up 6 IB.9± 1.5 O.I±0.9 0.3±O.3 21.4±0.B 0.7±1.l 13.8±32.2 14.7± ILl 
All values are means:': SO. 
a P<O.OS by paired t test and by Wilcoxon signed rank t test. 
b P<O.OI by paired t test and by Wilcoxon signed rank t test. 
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TABLE 5. Renal function and selected electrolytes in 31 children receiving renal allografts with Thymog1obulin or 
Campath preconditioning 
Blood urea 
Nitrogen Creatinine e-GFR Change in e-GFR tC02 Potassium Magnesium Uric acid 
Follow-up N (mgldL) (mgldL) (mUmin/1.73 m2) (mUmin/1.73 m2) (mmoUL) (mmoUL) (mgldL) (mgldL) 
2 weeks 34 22.1±1O.6 1.00±0.53 84.1 ::'::32.9 22.7::'::2.6 4.6±0.86 1.44::'::0.31 5.5± 1.8 
1 month 31 21.9± 13.8 0.87::'::0.43 82.4±.37.8 6.6±15.8 22.3±2.2 4.7±0.74 1.39±O.27 5.3±1.4 
3 months 29 19.0±5.80 0.93::'::0.51 87.2::'::27.8 6.3::'::29.1 22.2±2.8 4.7±0.72 1.39::'::0.28 5.5::'::1.5 
6 months 31 20.5±5.90 O.93±0.50 95.6::'::35.3 10.6::'::35.0 22.9±3.0 4.7±0.38 1.34±O.25 5.2± 1.5 
1 year 20 18.4±5.25 0.89±0.39 90.7±20.8 4.9±33.5 24.4::'::2.8 4.6±0.49 1.51 ±0.43 5.6::':: 1.3 
Latest follow up 20 19.0±5.30 1.03::'::0.49 88.0±21.8 3.2±40.1 23.9±2.9 4.4±0.47 1.5±0.25 5.2::':: 1.5 
e-GFR was calculated in 31/34 patients due to lack of height data in three patients. 
min/1.73 m2 with a mean value of 88 mL/min/1.73 m2 at 
latest follow-up. Also, blood urea nitrogen and serum creati-
nine, tC02, potassium, magnesium, and uric acid levels re-
mained constant and within the normal range (albeit after 
medical intervention in selected cases as noted above). Nota-
bly, at I-year follow-up preadolescent children in the current 
study had a GFR which was 18 ml/min/1.73 m2 higher than 
the historical case-matched controls (P<O.OS). 
As noted in Table 6, maintenance tacrolimus levels 
were significantly lower in the current preadolescents com-
pared to controls (P<O.OOI). 
DISCUSSION 
The current study is characterized by a high rate of suc-
cessful transition to once daily (94%) and to an every other 
day (96%) dosing oftacrolimus, and a low ACR rate (9%). 
Because previous studies have shown a high correlation be-
tween biopsy-confirmed renal allograft rejection and pres-
TABLE 6. Maintenance blood trough tacrolirnus levels 
(ng/rnL) in 15 current and control preadolescent children 
(P< 0.001)* 
Patient Current Controls 
1 3.2 7.3 
2 3.6 7.3 
3 2.6 5.9 
4 2.5 5 
5 5.9 8.9 
6 4.9 5.2 
7 <2.5 9.2 
8 5.8 7.4 
9 4.9 6.8 
10 <2.5 5 
11 2.6 5.7 
12 <2.5 9.7 
13 <2.5 8.3 
14 <2.5 7.5 
15 <2.5 7.4 
Total (means::'::SD) 3.43::':: 1.28 7.11::':: 1.52 
Six children in the current series had tacrolimus levels below the assay 
detection limit of <2.5 ng/mL. This limit was utilized for calculation of the 
above results. 
ence ofDSA (25-27), we took the precaution of returning two 
children who developed DSA to daily tacrolimus dosing. Al-
though neither child had any sign of rejection, both are con-
sidered failures of tacrolimus weaning. 
The regimen was well tolerated. Review of the compli-
cations and adverse effects (Table 3) indicates no instance of 
cytokine release syndrome when ATG or Campath were ad-
ministered with perioperative steroid prophylaxis. Also, all 
five children with delayed graft function had a rapid and com-
plete recovery of renal function. Such recovery may be en-
hanced by these preconditioning agents that effectively 
suppress ACR thereby permitting delayed use and lower 
amounts of tacrolimus, as noted previously (28). During a 
mean period of follow up of 1.33 years, we encountered three 
episodes of ACR two of which were associated with con-
firmed medical noncompliance. Despite the low blood 
trough tacrolimus levels, ACR was not encountered in the 
remaining 31 children. Moreover, this simple tacrolimus 
mono therapy regimen is devoid of body disfigurement and 
appears to be associated with excellent adherence. This con-
trasts with poor adherence with multidrug immunosuppres-
sive regimens particularly in adolescents with solid organ 
transplants in whom the incidence of noncompliance is four-
fold greater than in adults, and is a major cause of graft loss 
(29,30). 
Further review of the complications and adverse ef-
fects listed in Table 3 indicates that the rate of infection was 
low and the consequences of such infections were not se-
rious. No polyoma or parvovirus infections were observed. 
Despite a high rate ofEBV and CMV seronegativity, we did 
not observe EBV or CMV infections. Also, PTLD or overt 
malignancy did not occur during a follow-up period of up 
to 2.9 years. Other centers utilizing similar precondition-
ing agents have also noted a low incidence of opportunistic 
infectious, including CMV and EBV (31-33). Similarly, 
among 117 children receiving ATG for heart transplanta-
tion, only one developed PTLD (34). The low risk for 
PTLD may relate to inhibition of both T and B cells by ATG 
or Campath as well as the antiviral prophylaxis and low 
blood CNI levels in our patients. 
Neutropenia and autoimmune hemolytic anemia are 
the most clinically relevant complications and appear to be 
related to use of ATG or Campath. Currently it is not known 
if lower dosages of these agents may be effective in limiting 
ACR while preventing these hematologic disturbances. Al-
uctiOi i ul 
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though rapid lymphocyte depletion was anticipated with use 
of either preconditioning agent, the gradual and significant 
fall in neutrophil number during the first 6 months after 
transplantation was surprising (Table 2). In fact, the ANC 
remained 23% lower on latest follow-up compared to base-
line. Although previous studies have examined leukocyte 
subpopulations affected by Campath, a high incidence of 
neutropenia has not been previously reported in transplanted 
adults or children receiving ATG or Campath induction (8, 
28,34). These agents may be directly linked or may uncover a 
genetic predisposition to neutropenia. However, the mecha-
nism does not appear to involve antineutrophilic antibodies. 
While absolute neutropenia (ANC < 1500/mm3) occurred in 
10 children, severe neutropenia (ANC <1000/mm3) was ob-
served in two infants and in three older children over a period 
ranging from three weeks to 6 months after transplantation. 
Generally, this disorder was transient and responded to fil-
grastim administration. Remarkably, there was no serious 
morbidity associated with neutropenia. Of greater concern 
was the late development of autoimmune hemolytic anemia 
in two children who required hospitalization. In addition to 
the administration of filgrastim, strategies employed to re-
verse the neutopenia include decreasing the valganciclovir 
dosage and lowering tacrolimus blood levels as permitted by 
the child's clinical course. A brief course of corticosteroids 
and/or switching CNI to sirolimus may aid the reversal of 
hemolytic anemia. 
Because hypertension is a common disorder in pediat-
ric transplant recipients, we assessed its prevalence and 
course at various follow-up periods. Only three children 
(10%) in the current study developed new onset hyperten-
sion, which was transient. This incidence of hypertension was 
even lower than that observed with our previous protocol 
(35). Also, among 56% of the children with hypertension that 
predated transplantation, the prevalence of hypertension af-
ter transplantation fell to 15% and blood pressure was more 
manageable using fewer antihypertensive medications. 
New-onset posttransplant diabetes mellitus occurred 
in a single child with psychogenic polyphagia and rapid 
weight gain, and recurred in another child. This incidence is 
quite low compared with our previous tacrolimus-based im-
munosuppressive regimen (24, 35). Moreover, there was a 
low frequency of other metabolic disturbances, such as hy-
perkalemia, metabolic acidosis, hypomagnesemia, or hyper-
uricemia. These disorders were easily controlled and typically 
resolved after tacrolimus consolidation to once daily dosing 
by 6 months after transplantation. 
Previous reports describe diminished height Z-score 
and reduced growth velocity especially in preadolescents with 
advanced renal failure; such growth improves after trans-
plantation, but generally growth remains stunted with cyclos-
porine-based regimens that include steroids (36). In sharp 
contrast, in our preadolescent group (Table 4), the change in 
height Z-score increased by 1.3:±: 0.6 and by 1. 7:±: 1.0 standard 
deviations at 1 year and at latest follow-up, respectively, com-
pared to the time of transplantation (both P=O.OOI). Re-
markably, accelerated or catch-up growth occurred in 92% of 
this subgroup during the first year after transplantation. Fur-
thermore, this high rate of growth was sustained at latest 
follow-up. In fact, the change in height Z-score at 1 year in the 
current protocol far exceeds that of our case-matched con-
r t I klfl Ikil 
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troIs who were managed with rapid steroid tapering and with-
drawal at 6 months followed by tacrolimus monotherapy 
(P=0.02) (24). A greater, albeit statistically insignificant, 
height velocity was also noted in the current study compared 
to our case-matched controls. This apparent further acceler-
ation in growth likely results from steroid avoidance right 
after transplantation rather than because of a lesser exposure 
to tacrolimus per se. Modest but statistically insignificant in-
creases in height Z-score also occurred in the adolescent 
group. Moreover, this impressive growth was not associated 
with obesity which is very prevalent in children after renal 
transplantation, particularly if steroids are utilized for immu-
nosuppression. As shown in Table 4, there was no change in 
BMI in our overall group. BMI values above the 95th percen-
tile or WHI values exceeding 120% denoting obesity were 
uncommon, even when compared to healthy children in the 
general population (37). 
The mean e-GFR values of91 and 88 mL/min/1.73 m2 
at 1 year and at latest follow-up, respectively, in children 
managed with the current protocol (Table 5) parallel or ex-
ceed the excellent e-GFR reported previously (24). This is 
particularly evident in the preadolescent group, in which the 
GFR at 1 year significantly exceeded that of 15 historical case-
matched controls by 18 mL/min/l.73 m2 (P=O.05). This may 
be explained by a lower CNI exposure (Tables 1 and 6). Table 
6 shows that although the range of maintenance tacrolimus 
levels in the current preadolescents varied considerably, the 
majority of patients had significantly lower levels than the 
controls. Also, proteinuria as a marker of transplant glomeru-
lopathy was infrequent and transient. However, functional 
endpoints, such as e-GFR or proteinuria, are not suitable sur-
rogates for serial biopsies for detecting subclinical rejection or 
injury. Thus, a lack of protocol biopsies is an important lim-
itation of our study. 
CONCLUSION 
The simplicity, relative safety, and ability of the current 
immunosuppressive protocol to limit ACR and to maintain 
excellent renal function and promote growth over a period of 
up to 2.9 years merits further investigation. The potential of 
this protocol for better medical adherence, lesser CNI neph-
rotoxicity, and greater tolerogenicity may be of particular 
benefit to children with renal transplants. Close medical su-
pervision is essential in these children exposed to such low 
blood trough tacrolimus concentrations over many years. 
The benefit of this regimen in reducing the risk for CAN and 
in prolonging allograft survival remains to be determined. 
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